How a lipid transporter affects brain immune cells in Alzheimer's disease
Regulation of Microglial Activation State by a Lipid Transporter
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-10765729
This study is looking at how a protein called Spns2 affects brain immune cells that help keep our brains healthy, with the goal of finding new ways to manage or treat Alzheimer's disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10765729 on ClinicalTrials.gov |
What this research studies
This research investigates how a specific lipid transporter, Spinster homolog 2 (Spns2), influences the activation states of microglial cells, which are crucial for brain health. By understanding how these immune cells transition between inflammatory and anti-inflammatory states, the research aims to uncover potential therapeutic strategies for Alzheimer's disease. The study employs various experimental models, including those that mimic Alzheimer's pathology, to explore the role of S1P signaling in microglial function. Patients may benefit from insights gained about how to better manage or treat Alzheimer's disease through modulation of microglial activity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cognitive function and slow the progression of Alzheimer's disease.
How similar studies have performed: Other research has shown promising results in targeting microglial activation for neurodegenerative diseases, indicating that this approach has potential for success.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BIEBERICH, ERHARD — UNIVERSITY OF KENTUCKY
- Study coordinator: BIEBERICH, ERHARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease